Tissue Engineering Market to Grow at 12.95% CAGR Reaching USD 27.59 Billion by 2031, Driven by Advances in Regenerative Medicine and Biomaterials, Says Mordor Intelligence

The global tissue engineering market is projected to grow from USD 15.01 billion in 2026 to USD 27.59 billion by 2031, driven by advancements in regenerative medicine, biomaterials, and stem cell research. Key growth drivers include increasing demand for regenerative therapies, innovations in 3D bioprinting, rising prevalence of chronic diseases, and expanding applications in orthopedics, skin regeneration, and dental restoration. North America leads the market while Asia-Pacific emerges as a high-growth region.

04/24/2026, 3:54 AM • GlobeNewswire

Organogenesis Achieves Primary Endpoint in Randomized Controlled Trial of PuraPly®AM

Organogenesis Holdings Inc. announced that its randomized controlled trial of PuraPly®AM plus standard of care versus standard of care alone for non-healing diabetic foot ulcers achieved its primary endpoint, demonstrating statistically significant wound closure at 12 weeks (p<0.0477). The company plans to publish results in a peer-reviewed journal and believes the findings will support future coverage policies for the product.

04/06/2026, 7:02 PM • GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vizsla Silver Corp. - VZLA

Pomerantz LLP is investigating potential securities fraud claims on behalf of investors in Vizsla Silver Corp., following a security incident at its Mexico project site on January 29, 2026, where ten individuals were taken and operations were temporarily suspended. The incident triggered a 14.87% stock price decline. The firm is also investigating similar claims against Telesat Corporation and Organogenesis Holdings Inc.

02/03/2026, 1:59 PM • GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis Holdings Inc. - ORGO

Pomerantz LLP is investigating potential securities fraud claims against Organogenesis Holdings Inc. following the Centers for Medicare & Medicaid Services' withdrawal of Local Coverage Determinations for skin substitute grafts on December 26, 2025. The withdrawal exposes Organogenesis to increased competition from over 300 market participants. The company's stock price fell 10.14% to $5.28 per share on the news.

12/30/2025, 4:38 PM • GlobeNewswire

Global Wound Healing Devices Market Poised for Robust Growth at a CAGR of ~5% by 2032, Driven by Rising Chronic Wound Burden | DelveInsight

The global wound healing devices market is projected to grow from $29 billion in 2024 to $42 billion by 2032, driven by increasing chronic wounds, technological advancements, and an aging population.

11/20/2025, 1:00 PM • GlobeNewswire

Organogenesis Holdings Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – ORGO

DJS Law Group is investigating Organogenesis Holdings for potential securities law violations after the company's second phase 3 trial of ReNu failed to achieve its primary endpoint, causing a 12.39% stock price drop.

10/17/2025, 2:20 PM • Benzinga

Why Is Organogenesis Stock Trading Lower Friday?

Organogenesis Holdings reported results from its second Phase 3 trial for ReNu, a knee osteoarthritis treatment, which did not achieve statistical significance for its primary endpoint, causing the stock to drop 15.49%.

09/26/2025, 11:24 AM • Benzinga

12 Health Care Stocks Moving In Thursday's After-Market Session

Multiple healthcare stocks experienced significant price movements during Thursday's after-market trading session, with some companies seeing notable gains while others experienced declines.

09/25/2025, 5:06 PM • Benzinga

Organogenesis Provides Update on Second Phase 3 ReNu® Study

Organogenesis reported mixed results for its ReNu knee osteoarthritis treatment in a second Phase 3 trial, showing numerical improvement in pain reduction but not meeting the primary statistical endpoint. The company plans to request a pre-BLA meeting with the FDA to discuss potential approval.

09/25/2025, 4:50 PM • GlobeNewswire

Organogenesis Provides Update on Second Phase 3 ReNu® Study

Organogenesis reported results from its second Phase 3 trial for ReNu, a knee osteoarthritis treatment, which did not meet the primary endpoint but showed numerical improvement in pain reduction. The company plans to request a pre-BLA meeting with the FDA to discuss submission pathway.

09/25/2025, 4:50 PM • Benzinga

Global Amniotic Membrane Market Poised for Extraordinary Growth at a CAGR of ~7% by 2032 | DelveInsight

The global amniotic membrane market is expected to grow at a 7% CAGR by 2032, driven by increasing demand for advanced wound healing treatments and ophthalmological applications, with North America leading market expansion.

07/30/2025, 1:00 PM • GlobeNewswire